SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Linehan WM, Zbar B, Bates SE, Zelefsky MJ, Yang JC. Cancer of the kidney and ureter. In: DeVitaVT, HelmannS, RosenbergSA, editors. Cancer: principles and practice in oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001: 13621384.
  • 2
    Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989; 7: 18631874.
  • 3
    Atkins MB, Sparano J, Fisher RI, et al. Randomized Phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol. 1993; 11: 661670.
  • 4
    Marincola FM, White DE, Wise AP, Rosenberg SA. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol. 1995; 13: 11101112.
  • 5
    Négrier S, Escudier B, Lasset C, et al. Interleukin-2, interferon or both in 425 patients with metastatic renal cell cancer: results of a multicenter randomized trial. N Engl J Med. 1998; 338: 12721278.
  • 6
    Buter J, Sleijfer DT, van der Graaf WT, de Vries EG, Willemse PH, Mulder NH. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Semin Oncol. 1993; 20: 1621.
  • 7
    Atzpodien J, Kirchner H, Hänninen EL, et al. European studies of interleukin-2 in metastatic renal cell carcinoma. Semin Oncol. 1993; 20 (Suppl 9): 2226.
  • 8
    Lissoni P, Barni S, Ardizzoia A, et al. Prognostic factors for the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncology. 1994; 51: 5962.
  • 9
    Tourani JM, Lucas V, Mayeur D, et al. Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP 1 trial. Ann Oncol. 1996; 7: 525528.
  • 10
    Yang JC, Rosenberg SA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am. 1997; 3: S79S84.
  • 11
    Ravaud A, Négrier S, Cany L, et al. Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. Br J Cancer. 1994; 69: 11111114.
  • 12
    Atzpodien J, Hänninen EL, Kirchner H, et al. Multiinstitutional home-therapy trial of recombinant interleukin-2 and interferon alfa-2a in progressive metastatic renal cell carcinoma. J Clin Oncol. 1995; 13: 497501.
  • 13
    Dutcher JP, Atkins M, Fisher R, et al. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989–1997. Cancer J Am Sci Am. 1997; 3: S73S78.
  • 14
    Tourani J, Pfister C, Berdah J, et al. Subcutaneous (SC) interleukin-2 (IL-2) plus alpha-interferon (IFN-α) in outpatient with metastatic renal cell carcinoma (MRCC). SCAPP III trial [abstract 1313]. Proc Am Soc Clin Oncol. 2000; 19: 334a.
  • 15
    Mc Dermott D, Flaherty L, Clark J, et al. A randomized Phase III trial of high-dose interleukin-2 (HD IL-2) versus subcutaneous (SC) IL-2/interferon (IFN) in patients with metastatic renal cell carcinoma (RCC) [abstract 685]. Proc Am Soc Clin Oncol. 2001; 20: 172a.
  • 16
    Hofmockel G, Langer W, Theiss M, Gruss A, Frohmuller HG. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-α and 5-fluorouracil. J Urol. 1996; 156: 1821.
  • 17
    Joffe JK, Banks RE, Forbes MA, et al. A Phase II study of interferon-α, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol. 1996; 77: 638649.
  • 18
    Ellerhorst JA, Sella A, Amato RJ, et al. Phase II trial of 5-fluorouracil, interferon-α and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer. 1997; 80: 21282132.
  • 19
    Ravaud A, Audhuy B, Gomez F, et al. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter Phase II trial. J Clin Oncol. 1998; 16: 27282732.
  • 20
    Tourani JM, Pfister C, Berdah JF, et al. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized Phase II study. J Clin Oncol. 1998; 16: 25052513.
  • 21
    Elias L, Lew D, Figlin RA, et al. Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a Southwest Oncology Group Phase II study. Cancer. 2000; 89: 597603.
  • 22
    Allen MJ, Vaughan M, Webb A, et al. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a Phase II study. Br J Cancer. 2000; 83: 980985.
  • 23
    van Herpen CM, Jansen RL, Kruit WH, et al. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter Phase II study. Dutch Immunotherapy Working Party. Br J Cancer. 2000; 82: 772776.
  • 24
    Dutcher JP, Logan T, Gordon M, et al. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res. 2000; 6: 34423450.
  • 25
    Négrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal cell carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with and without fluorouracil. J Clin Oncol. 2000; 18: 40094015.
  • 26
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47: 207214.
  • 27
    Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chron Dis. 1961; 13: 346353.